Generic placeholder image

Current Organocatalysis

Editor-in-Chief

ISSN (Print): 2213-3372
ISSN (Online): 2213-3380

Mini-Review Article

Remdesivir in Severe Cases of COVID-19 Infection

In Press, (this is not the final "Version of Record"). Available online 30 April, 2024
Author(s): Alberto Boretti*
Published on: 30 April, 2024

DOI: 10.2174/0122133372290992240409084133

Price: $95

Abstract

Background: Assessing the efficacy of remdesivir for COVID-19 infection holds historical significance. Understanding its effectiveness from previous pandemic instances can enable us to gain insights into its efficacy, informing our strategies for responding to future outbreaks or variants.

Objective: Gaining an insight into the historical efficacy of remdesivir can offer valuable data for evaluating the advancement of COVID-19 treatments and the development of medical expertise in handling the disease.

Method: The historical data regarding the effectiveness of remdesivir can enrich the pool of knowledge and evidence accessible for public health planning and decision-making. Understanding whether remdesivir was efficacious in previous instances may aid in comprehending its real-world impact on patient outcomes at those times. Such insights are crucial for evaluating treatment efficacy and refining strategies based on past experiences.

Results: In the late treatment of severe COVID-19 cases, which are particularly challenging, remdesivir has demonstrated a 6% improvement.

Conclusion: The 6% enhanced effect of remdesivir is not substantial, considering that it is an unweighted average of works with varying degrees of importance and reliability. Additionally, there are instances where conflicts of interest may have impacted the results. It is also possible that the observed improvement could be attributed to better patient care in certain environments.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy